Year: 2026

CALGARY, Alberta, May 21, 2026 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (TSX – PEY) (“Peyto“) is pleased to announce that the nominees listed in the information circular – proxy statement dated April 2, 2026 were elected as directors of Peyto at Peyto’s annual meeting of shareholders (the “Meeting“) held on May 21, 2026. The detailed results of the votes for the election of directors, the appointment of auditors and the advisory vote on executive compensation held at the Meeting are set out below. Election of Directors On a vote by ballot, each of the following nine nominees proposed by management was elected as a director of Peyto:Nominee   Outcome of Vote   Votes For   VotesWithheldDonald Gray   Elected   95,697,898   7,796,825Brian Davis   Elected   96,684,903   6,809,820Darren...

Last Patient In enrolled ahead of schedule; interim analysis anticipated by year-end 2026 to inform plans for the next stage of development  TAIPEI, May 21, 2026 (GLOBE NEWSWIRE) — TaiMed Biologics (TPEX: 4147) today announced the completion of enrollment in its Phase 2b clinical study evaluating TMB-365/380, a novel investigational long-acting dual-antibody regimen for HIV maintenance therapy. The study reached Last Patient In (LPI) ahead of the planned schedule, marking an important operational milestone for the program. The Phase 2b study is designed to evaluate the efficacy and safety of TMB-365/380 as an every-two-month (Q2M), first-line HIV maintenance therapy for people living with HIV. With enrollment now complete, participants will continue scheduled follow-up, and TaiMed expects to report an interim analysis by year-end...

Award marks Rocket Lab’s first satellite production program for geostationary orbit and continues a Space Systems Command program for development and delivery on orbit of two Heimdall prototype payloads by Rocket Lab Optical SystemsRocket Lab’s Lightning Spacecraft Production LineRocket Lab has been awarded a $90 million contract by the U.S. Space Force’s Space Systems Command (SSC) to design, manufacture, integrate, and operate two geostationary (GEO) satellites hosting the Heimdall space domain awareness (SDA) payload.LONG BEACH, Calif., May 21, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) a leading launch and space systems company, today announced it has been awarded a $90 million contract by the U.S. Space Force’s Space Systems Command (SSC) to design, manufacture, integrate,...

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA. Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate (“ORR”) per RECIST 1.1, as assessed by the Independent Review Committee (“IRC”). As of the data cut-off of October 8, 2025, the IRC-assessed ORR was 32.3% (95%CI: 21.2%, 45.1%), exceeding...

ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO’s official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company’s three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575);...

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) — Purecore Metals Inc. (CSE: PURE) (“Purecore” or the “Company”) is pleased to announce that it has engaged HEG & Associates Exploration Services Inc. (“HEG”) to plan and execute the Company’s 2026 exploration program at the Bankier Property, located in the Similkameen and Osoyoos Mining Divisions of southern British Columbia. About HEG HEG is a Kelowna-based geological services company specializing in exploration programs throughout the Okanagan region and similar geological settings. The company focuses on advancing early-stage projects through systematic, cost-effective field programs while maintaining operational flexibility and responsible exploration practices. With its head office located approximately 50 minutes from the Bankier Property, HEG is well positioned...

Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquartered in Tulsa, Oklahoma. The Agreement grants Fission exclusive worldwide rights to import, market, distribute, and sell HBC’s ProGo® salmon-derived bioactive peptide ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel. To secure exclusivity, Fission shall purchase and pay for a minimum of $3m of ProGo® on or before 31 January 2027. The Parties have further agreed a projection of over $5m ProGo® on an annualised basis for HBC’s capacity allocation and inventory planning. The exclusivity period runs through 31 January 2027, after which the supply relationship continues between the Parties on a non-exclusive...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 21, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland” or “Corporation”) (TSX-V: MD) is pleased to announce that it has completed a second and final tranche of its previously announced non-brokered private placement by issuing 6,926,123 units of Midland at a price of $0.45 per unit for aggregate gross proceeds of $3.1 million. Each unit consists of one common share and one warrant. Each warrant entitles the holder to purchase one common share of Midland at a price of $0.65 for a period of two years from the date of issuance. The total gross proceeds for this tranche and the one previously closed on May 11, 2026 is $5.3 million. Institutional investors have participated in the second tranche of the private placement,...

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago. Enrollment is ongoing in ASCEND (NCT07335497), a global, open-label Phase 1/2 clinical trial...